Breaking News
Illumina
About Illumina
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa
March 24 2023
Illumina, a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative genomics […]
Illumina Unveils its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities
July 28 2022
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the […]
Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy
May 24 2022
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the […]
Illumina and Allegheny Health Network to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care
May 19 2022
Illumina, Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, and Allegheny Health […]
Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership
January 11 2022
Illumina Inc. (NASDAQ: ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) […]
SomaLogic Announces Exclusive Partnership with Illumina to Develop Sequencing-based Proteomic Solutions
January 6 2022
SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a worldwide strategic collaboration […]
BICO Announces Appointment of Susan Tousi as New Member of the Board of Directors
November 18 2021
Today BICO, the world’s leading Bio Convergence company announced it has added Susan Tousi to […]
Whole Genome Sequencing Improves Diagnosis of Rare Diseases and Shortens Diagnostic Journeys for Patients, According to World First Study
November 11 2021
A world-first scientific study, published today in the New England Journal of Medicine, has shown that […]
Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL
October 15 2021
Illumina, Inc. (NASDAQ:ILMN) today announced that Bob Ragusa has been appointed as Chief Executive Officer of GRAIL, […]